Tuberculosis is a long-standing global health issue that requires continued public health vigilance to prevent a resurgence of this preventable and curable disease.
Lisa Nodzon, PhD, ARNP, AOCNP; Katie Tobon, PharmD, BCOP; and Javier Pinilla-Ibarz, MD, PhD, share insight on strategies for the monitoring and management of BTK inhibitor–associated toxicities in CLL and review the importance of a multidisciplinary approach to treatment.
The radiation emerging from these isotopes can be used in 2 different ways in cancer trials: imaging (detection of tumors) and therapy (destruction of tumors).
As pharmacists were pulled into patient-facing roles, many hospitals were forced to scale back or make adjustments in medication compounding practices.
Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.
Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.
Students should ask questions and stay engaged in their education.
Idiopathic intracranial hypertension was previously considered a rare condition, however, its prevalence is increasing in parallel with obesity in patient populations.
Advanced cell therapies are now saving the lives of people whose blood cancer would previously have been incurable. While the UK was quick to recognize the potential of these innovative therapies, patient access to these therapies may change without continued investment in the UK's cell therapy infrastructure.
Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.
Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.
Students are being exposed to new patient experiences through collaboration with practitioners.
The TJC and IHI advocate for medication reconciliation at all transitions of care.
Although quality of life has significantly improved for patients with HIV, there are several factors influencing how we provide care and treat patients now and in the future.
The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
This medication is associated with a number of adverse effects, such as gastrointestinal upset and peripheral neuropathies, that may be mitigated by less frequent dosing.
Individualized treatments like cell and gene therapies are poised to scale rapidly over the next decade.
John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.
An overview of acid reflux and gastroesophageal reflux disease, over-the-counter options, long-term effects of proton pump inhibitors, lifestyle recommendations, and when to refer patients.
A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.
More drugs plus a growing population of older and sicker patients is creating medication-alert overload for already stressed clinicians.
Incorporating AI into pharmacy education is crucial to training on its appropriate use.
Holistic and compassionate counseling by a pharmacist and pharmacy-interns on-duty over weekends could positively impact patient lives, especially for older adults and economically disadvantaged patients.
The study implemented a novel workflow for ambulatory care pharmacists to execute pharmacist-administered depression screenings.
Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.
Though new treatments offer hope, careful monitoring and understanding of risks remain essential for their success.
Creating a free app to assist in vancomycin dosing proved to be an entertaining and enlightening journey.
Working for the USPHS offers unique compensation and quality-of-life benefits.
There are no clearly defined, widely accepted clinical pharmacist metrics.